Data were last evaluated in IARC (1994).

## **1. Exposure Data**

## 1.1 Chemical and physical data

1.1.1 Nomenclature

Chem. Abstr. Serv. Reg. No.: 78-79-5 Chem. Abstr. Name: 2-Methyl-1,3-butadiene IUPAC Systematic Name: Isoprene Synonym: Isopentadiene

1.1.2 Structural and molecular formulae and relative molecular mass

$$CH_3$$
  
 $\downarrow$   
 $CH_2 = C - CH = CH_2$ 

 $C_5H_8$ 

Relative molecular mass: 68.12

- 1.1.3 Chemical and physical properties of the pure substance
  - (a) Description: Colourless, volatile liquid (Budavari, 1996)
  - (b) Boiling-point: 34.0°C (Lide, 1997)
  - (c) Melting-point: -149.5°C (Lide, 1997)
  - (d) Solubility: Practically insoluble in water; miscible with ethanol and diethyl ether (Budavari, 1996)
  - (e) Vapour pressure: 66 kPa at 20°C; relative vapour density (air = 1), 2.35 (Verschueren, 1996)
  - (f) Flash-point: -48°C (Lewis, 1993)
  - (g) Conversion factor:  $mg/m^3 = 2.79 \times ppm$

## **1.2 Production and use**

Production of isoprene in the United States in 1993 was reported to be 276 841 tonnes (United States International Trade Commission, 1994). Production capacities for isoprene in 1987 were estimated to be (thousand tonnes): United States, 199; the Netherlands, 25; Republic of South Africa, 45; Japan, 105; and the former Soviet Union, about 800 (Weitz & Loser, 1989). In 1992, isoprene monomer reportedly was produced in Brazil, the Netherlands, Japan, Romania, countries of the former Soviet Union and the United States (Lybarger, 1995).

-1015-

## IARC MONOGRAPHS VOLUME 71

Almost all isoprene produced is used in the preparation of polymers and copolymers. cis-Polyisoprene, primarily for vehicle tyres, is the largest application, with styrene–isoprene–styrene (SIS) block polymers being a rapidly growing secondary application. Butyl rubber is a significant third application. World demand for isoprene for monomer use in 1992 was (thousand tonnes): polyisoprene, 827; SIS, 95; butyl rubber, 25; and other uses, 10 (Weitz & Loser, 1989; Lybarger, 1995).

## 1.3 Occurrence

1016

## 1.3.1 Occupational exposure

According to the 1981–83 National Occupational Exposure Survey (NOES) in the United States (NOES, 1997), approximately 4000 workers in the United States were potentially exposed to isoprene (see General Remarks). Occupational exposures to isoprene occur mainly in the production of the monomer and of synthetic rubbers.

## 1.3.2 Environmental occurrence

Isoprene occurs in the environment as emissions from vegetation, particularly from deciduous forests, and as a by-product in the production of ethylene by naphtha cracking. In the United States, the total emission rate of isoprene from deciduous forests has been estimated at 4.9 tonnes per year, with greatest emissions in the summer. The global annual emission of isoprene in 1988 was estimated to be 285 000 thousand tonnes. Isoprene is produced endogenously in humans. It has also been found in tobacco smoke, gasoline, turbine and automobile exhaust, and in emissions from wood pulping, biomass combustion and rubber abrasion (United States National Library of Medicine, 1997).

## 1.4 Regulations and guidelines

The American Conference of Governmental Industrial Hygienists (ACGIH) (1997) has not proposed any occupational exposure limits for isoprene in workplace air. Poland has an 8-h time-weighted average threshold limit value of 100 mg/m<sup>3</sup> and Russia has a short-term exposure limit of 40 mg/m<sup>3</sup> for exposure in workplace air (International Labour Office, 1991)

No international guideline for isoprene in drinking-water has been established (WHO, 1993).

# 2. Studies of Cancer in Humans

No data were available to the Working Group.

## **3.** Studies of Cancer in Experimental Animals

Isoprene was tested for carcinogenicity in male mice and in male rats by inhalation exposure in one-year studies. In mice, exposure to isoprene resulted in increased incidence of benign and malignant tumours of the lung, liver and forestomach and of Harderian gland adenomas. The study by inhalation in rats was inadequate for an assessment of carcinogenicity (IARC, 1994).

## 3.1 Inhalation

## 3.1.1 *Mouse*

Groups of 50 male B6C3F<sub>1</sub> mice [age unspecified] were exposed to isoprene by whole-body inhalation at concentrations of 0, 10, 70, 140, 280, 700 or 2200 ppm [0, 28, 200, 400, 800, 2000 or 6160 mg/m<sup>3</sup>] for 4 or 8 h per day on five days per week for 20, 40 or 80 weeks, followed by holding periods until termination of the experiment at 96 or 104 weeks. The isoprene was > 99% pure, containing less than 1% limonene and less than 100 ppm *tert*-butyl catechol. Similar groups of female mice were exposed to 0, 10 or 70 ppm for 80 weeks and held until 104 weeks. All animals received a complete gross necropsy and major tissues and organs were examined histologically. Survival of groups exposed to 280 ppm for 80 weeks or to higher concentrations was less than that of controls and less than 50%. As shown in Table 1, increases in tumour incidence were found in the lung, liver, heart, spleen and Harderian gland in males. In female mice, increased incidence of Harderian gland adenomas (2/49 controls, 3/49 10-ppm and 8/49 (p < 0.05) 70-ppm) was seen at the high dose (Cox *et al.*, 1996; Placke *et al.*, 1996).

#### 3.1.2 Rat

Groups of 50 male and 50 female Fischer 344/N rats, six weeks of age, were exposed to isoprene (> 99% pure) by whole-body inhalation at concentrations 0, 220, 700 or 7000 ppm [0, 614, 1953 or 19 530 mg/m<sup>3</sup>] for 6 h per day on five days per week for 104 weeks. Animals received a complete gross examination and major tissues and organs were evaluated histologically. Survival of exposed rats was similar to that of controls (males: control, 18/50; low-dose, 16/50; mid-dose, 15/50; high-dose, 15/50; females: 29/50, 30/50, 28/50, 27/50), and weight gain was not affected by the exposures. Exposed males and females had increased incidences of mammary fibroadenomas (males: control, 2/50; low-dose, 4/50; mid-dose, 6/50; high-dose, 21/50; females, 19/50, 35/50, 32/50, 32/50). The incidence of renal tubule adenomas was increased in treated males (2/50, 4/50, 8/50, 15/50). Some animals also had a renal carcinoma. Treated males also had increased incidence of interstitial-cell adenomas of the testis (33/50, 37/50, 44/50, 48/50) (United States National Toxicology Program, 1997).

|  | <i>i</i> 1     | •                 |                    | I                  |                     |                     | -                     |                     |                        |                         |                         |                          |
|--|----------------|-------------------|--------------------|--------------------|---------------------|---------------------|-----------------------|---------------------|------------------------|-------------------------|-------------------------|--------------------------|
| Group<br>ppm/weeks<br>ppm × weeks <sup>a</sup> | 1<br>0/80<br>0 | 2<br>10/80<br>800 | 3<br>70/40<br>2800 | 4<br>70/80<br>5600 | 5<br>140/40<br>5600 | 6<br>280/20<br>5600 | 7<br>280/80<br>22 400 | 8<br>700/80<br>5600 | 9<br>2200/20<br>22 000 | 10<br>2200/80<br>77 000 | 11<br>2200/40<br>88 000 | 12<br>2200/80<br>176 000 |
| Alveolar/bronchiolar                           |                |                   |                    |                    |                     |                     |                       |                     |                        |                         |                         |                          |
| Adenoma  | 11/50          | 16/50             | 8/50               | 4/50               | 10/50               | 16/50               | 13/50                 | 23/50*              | 14/50                  | 15/50                   | 29/49*                  | 30/50*                   |
| Carcinoma                                      | 0              | 1                 | 0                  | 2                  | 1                   | 3                   | 1                     | 7*                  | 2                      | 3                       | 3                       | 7*                       |
| Hepatocellular                                 |                |                   |                    |                    |                     |                     |                       |                     |                        |                         |                         |                          |
| Adenoma  | 11/50          | 12/50             | 14/49              | 15/50              | 22/50*              | 18/49               | 24/50*                | 27/48*              | 22/50*                 | 21/50*                  | 28/47*                  | 30/50*                   |
| Carcinoma                                      | 9              | 6                 | 11                 | 9                  | 10                  | 12                  | 16                    | 17                  | 12                     | 15                      | 18*                     | 16                       |
| Harderian gland                                |                |                   |                    |                    |                     |                     |                       |                     |                        |                         |                         |                          |
| Adenoma  | 4/47           | 4/49              | 13/48              | 9/50               | 12/50*              | 16/49*              | 17/50*                | 26/49*              | 19/49*                 | 28/50*                  | 31/49*                  | 35/50*                   |
| Carcinoma                                      | 0              | 0                 | 0                  | 0                  | 2                   | 3                   | 1                     | 3                   | 1                      | 2                       | 0                       | 2                        |
| Haemangiosarcoma                               |                |                   |                    |                    |                     |                     |                       |                     |                        |                         |                         |                          |
| Heart  | 0/49           | 0/50              | 0/49               | 0/50               | 0/50                | 0/50                | 2/50                  | 1/50                | 4/50                   | 1/50                    | 1/49                    | 1/50                     |
| Spleen   | 1/49           | 3/48              | 1/47               | 2/50               | 3/50                | 2/47                | 1/50                  | 2/48                | 2/48                   | 2/50                    | 0/47                    | 1/49                     |
| Histiocytic sarcomab                           | 0/50           | 2/50              | 2/50               | 2/50               | 1/59                | 8/50*               | 4/50                  | 2/50                | 5/50*                  | 7/50*                   | 7/50*                   | 2/50                     |

Table 1. Summary of isoprene exposure-related neoplasms in male B6C3F1 mice

From Placke et al. (1996) and Cox et al. (1996)

<sup>a</sup> Groups 9 and 10 were exposed for 4 h per day instead of 8 h per day

<sup>b</sup> Found in kidney, lung, liver, lymph nodes, bone marrow and spleen

\* Incidence significantly greater than in the control group (p < 0.05, Fisher's exact test).

# 4. Other Data Relevant to an Evaluation of Carcinogenicity and its Mechanisms

## 4.1 Absorption, distribution, metabolism and excretion

## 4.1.1 Humans

Isoprene is formed endogenously at the rate of 0.15  $\mu$ mol/kg per hour in man. No further data were available to the Working Group (IARC, 1994).

## 4.1.2 Experimental systems

Isoprene is formed endogenously at the rate of 1.9  $\mu$ mol/kg per hour in both rats and mice. 1,2-Epoxy-2-methyl-3-butene (80%) and 3,4-epoxy-2-methyl-1-butene (20%) are two major metabolites in mouse liver microsomes. The 3,4-epoxide can be further metabolized to isoprene diepoxide. Both rats and mice exhibited saturation kinetics when exposed to isoprene at concentrations above 300 ppm [837 mg/m<sup>3</sup>]. The maximal rate of metabolism *in vivo* is more than three times greater in mice than in rats (IARC, 1994).

The most important enzyme converting isoprene to both monoepoxides and also to the diepoxide is CYP2E1, as shown by both recombinant expressed enzymes and in human liver microsomes (Bogaards *et al.*, 1996).

Both rat and mouse liver microsomes are able to catalyse the formation of isoprene monoepoxides (Bogaards *et al.*, 1996).

## 4.1.3 Comparison of human and rodent data

The intrinsic rates of formation of monoepoxides in human, rat and mouse liver microsomes are roughly similar, when epoxide hydrolase is inhibited, whereas the amount of monoepoxides at the end of incubation is two and even 15 times higher in mouse liver microsomes than in rat and human liver microsomes, respectively (Bogaards *et al.*, 1996). Thus, differences in epoxide hydrolase activity between different species may be of importance for toxicological outcomes.

A physiological toxicokinetic model has been developed for inhaled isoprene in mouse, rat and humans, taking into account published or assumed kinetic parameters (Filser *et al.*, 1996). On the basis of this model, at human exposure conditions (up to 50 ppm [140 mg/m<sup>3</sup>]), rates of metabolism are about 14 times faster in mice and about eight times faster in rats than in humans.

## 4.2 Toxic effects

### 4.2.1 Humans

Increasing duration of employment of isoprene rubber production workers showed a correlation with the prevalence and degree of various effects (IARC, 1994). Effects noted in these workers were subtrophic and atrophic processes in the upper respiratory tract, catarrhal inflammation, and degeneration of the olfactory tract.

#### IARC MONOGRAPHS VOLUME 71

### 4.2.2 *Experimental systems*

Inhalation exposure to isoprene (0, 438, 875, 1750, 3500 or 7000 ppm [1222– 19 530 mg/m<sup>3</sup>]) for 6 h per day on five days per week for two weeks did not affect survival, body weight gain, clinical signs or haematological parameters in male or female Fischer 344 rats. However, both male and female B6C3F<sub>1</sub> mice exposed under identical conditions had reduced erythrocyte numbers, haemoglobin concentrations and volume of packed erythrocytes, without increases in reticulocytes and polychromatic erythrocytes. In addition, both male and female mice exhibited forestomach epithelial hyperplasia at exposures  $\geq$  438 ppm. Male B6C3F<sub>1</sub> mice exposed to  $\geq$  1750 ppm had degeneration of the olfactory epithelium, and 7000 ppm isoprene caused reduced body weight gain and atrophy of the thymus and testis in these mice (Melnick *et al.*, 1990).

Male Fischer 344 rats and B6C3F<sub>1</sub> mice were exposed by inhalation to 0, 70, 220, 700, 2200 or 7000 ppm [195–19 530 mg/m<sup>3</sup>] isoprene for 6 h per day on five days per week for 26 weeks and were monitored for a further 26 weeks post-exposure. All exposure doses induced neoplastic and proliferative lesions in the liver, lung, Harderian gland and forestomach of mice. Exposure to 7000 ppm reduced survival in mice. There was an increase in altered hepatocellular foci and incidence of forestomach hyperplasia at doses  $\geq$  700 ppm [1950 mg/m<sup>3</sup>]. At the end of the 26-week recovery period, alveolar epithelial hyperplasia was increased in the 700 ppm and higher-dose groups, alveolar/bronchiolar neoplasms were increased in the  $\geq$  2200-ppm and 7000-ppm groups and spinal cord degeneration was evident in all dose groups. Rats exposed to  $\geq$  700 ppm isoprene developed interstitial-cell hyperplasia of the testis (Melnick *et al.*, 1994, 1996).

## 4.3 Reproductive and developmental effects

## 4.3.1 Humans

No data were available to the Working Group.

### 4.3.2 *Experimental systems*

Sprague-Dawley rats and Swiss CD-1 mice were exposed by inhalation to 0, 280, 1400 or 7000 ppm [800–19 530 mg/m<sup>3</sup>] isoprene for 6 h per day on seven days per week on gestational days 6–19 (rats) or 6–17 (mice) (IARC, 1994). There was no adverse effect on rat dams or other reproductive index at any dose level. The only fetal malformation observed in rats was reduced ossification of the vertebral centra, which occurred at 7000 ppm isoprene. In mice, there was reduced fetal body weight at all dose levels and decreased maternal weight gain in the 7000-ppm group. Also in the 7000-ppm group, there was an increased incidence of supernumerary ribs but no increase in fetal malformations.

B6C3F<sub>1</sub> mice were exposed by inhalation to 0, 70, 220, 700, 2200 or 7000 ppm [200–19 530 mg/m<sup>3</sup>] isoprene for 6 h per day on five days per week for 13 weeks. Effects observed in the males were reduction of testicular weight by 35% in the animals exposed to 7000 ppm, seminiferous tubular atrophy in 20% of animals studied, reduced epididymal weights, lower spermatid headcounts and concentrations, and reduced sperm

1020

motility in the 700- and 7000-ppm groups. Female mice in the 7000-ppm group had significantly longer average oestrous cycles (Melnick *et al.*, 1994).

Isoprene [7.34 mmol/kg bw by intraperitoneal injection] affected ovarian follicles in 21-day-old B6C3F<sub>1</sub> mice. Small (primordial) follicle counts were reduced by  $76 \pm 5\%$ ; while growing (primary to pre-antral) follicle counts were reduced by  $46\% \pm 8\%$  when compared with the respective sesame seed oil controls (Doerr *et al.*, 1995).

## 4.4 Genetic and related effects

4.4.1 *Humans* 

No data were available to the Working Group.

## 4.4.2 *Experimental systems* (see Table 2 for references)

Isoprene did not induce mutations in bacteria or, in single studies, either sister chromatid exchangess or chromosomal aberrations in cultures of Chinese hamster ovary cells. An inhalation study with mice demonstrated that isoprene could induce sister chromatid exchanges and micronuclei in bone-marrow cells. No increase in the incidence of chromosomal aberrations was observed in the same study.

Isoprene can be metabolized by mouse liver microsomes to oxirane intermediates, the main metabolite being 1,2-epoxy-2-methyl-3-butene. Neither this metabolite nor 3,4-epoxy-2-methyl-1-butene was mutagenic to *Salmonella typhimurium* TA100 or TA98 when tested up to lethal concentrations (30 mM), whereas another possible minor metabolite, 2-methyl-1,2,3,4-diepoxybutane was mutagenic in *S. typhimurium* TA100. The diepoxide had a high rate of nicotinamide alkylation (Gervasi *et al.*, 1985). Isoprene has been shown to bind covalently to haemoglobin in rat and mice *in vivo*.

## 5. Summary of Data Reported and Evaluation

## 5.1 Exposure data

Exposure to isoprene occurs in the production of the monomer and in the production of synthetic rubbers. Isoprene occurs in the environment due to emissions from vegetation and the production of ethylene by naphtha cracking.

### 5.2 Human carcinogenicity data

No data were available to the Working Group.

### 5.3 Animal carcinogenicity data

Isoprene was tested for carcinogenicity in mice and rats by inhalation exposure. In two studies in mice, exposure to isoprene resulted in increased combined incidences of benign and malignant tumours of the lung and liver and of Harderian gland adenomas. In one study, haemangiosarcomas of the heart and spleen and histiocytic sarcomas were also found in male mice, as well as increased incidences of pituitary adenomas and Harderian

| Test system   | Result <sup>a</sup>                             |  | Dose <sup>b</sup><br>(LED or HID) | Reference                                |  |  |
|---|---|--|-----------------------------------|--|--|--|
|   | Without<br>exogenous<br>metabolic<br>activation | With<br>exogenous<br>metabolic<br>activation | (LED OF HID)                      |  |  |  |
| SA0, Salmonella typhimurium TA100, reverse mutation                                       | _   | _  | 680                               | de Meester et al. (1981)                 |  |  |
| SA0, Salmonella typhimurium TA100, reverse mutation                                       | _   | _  | 5000                              | Mortelmans et al. (1986)                 |  |  |
| SA3, Salmonella typhimurium TA1530, reverse mutation                                      |   |  | 680                               | de Meester et al. (1981)                 |  |  |
| SA5, Salmonella typhimurium TA1535, reverse mutation                                      | _   | _  | 680                               | de Meester et al. (1981)                 |  |  |
| SA5, Salmonella typhimurium TA1535, reverse mutation                                      | _   | _  | 5000                              | Mortelmans et al. (1986)                 |  |  |
| SA7, Salmonella typhimurium TA1537, reverse mutation                                      | _   | _  | 5000                              | Mortelmans et al. (1986)                 |  |  |
| SA8, Salmonella typhimurium TA1538, reverse mutation                                      | _   | _  | 680                               | de Meester et al. (1981)                 |  |  |
| SA9, Salmonella typhimurium TA98, reverse mutation  | _   | _  | 680                               | de Meester et al. (1981)                 |  |  |
| SA9, Salmonella typhimurium TA98, reverse mutation  | _   | _  | 5000                              | Mortelmans et al. (1986)                 |  |  |
| SIC, Sister chromatid exchange, Chinese hamster ovary CHO cells<br>in vitro               | -   | -  | 5000                              | US National Toxicology<br>Program (1995) |  |  |
| CIC, Chromosomal aberrations, Chinese hamster ovary CHO cells                             | _   | _  | 5000                              | US National Toxicology<br>Program (1995) |  |  |
| SVA, Sister chromatid exchange, B6C3F <sub>1</sub> mouse bone-marrow cells <i>in vivo</i> | +   |  | 430 inh 6 h/d $\times$ 12         | Tice <i>et al.</i> (1988)                |  |  |
| MVM, Micronucleus test, B6C3F <sub>1</sub> mouse bone-marrow cells <i>in vivo</i>         | +   |  | 430 inh 6 h/d $\times$ 12         | Tice et al. (1988)                       |  |  |
| CBA, Chromosomal aberrations, B6C3F <sub>1</sub> mouse bone-marrow cells <i>in vivo</i>   | -   |  | 6900 inh 6 h/d × 12               | Tice et al. (1988)                       |  |  |
| BVP, Binding (covalent) male B6C3F <sub>1</sub> mouse haemoglobin in vivo                 | +   |  | $2 \text{ ip} \times 1$           | Sun et al. (1989)                        |  |  |
| BVP, Binding (covalent) male Sprague-Dawley rat haemoglobin <i>in vivo</i>                | +   |  | $2 \text{ ip} \times 1$           | Sun et al. (1989)                        |  |  |
| BVP, Binding (covalent) B6C3F1 mouse haemoglobin in vivo                                  | +   |  | 60 inh 6 h                        | Bond et al. (1991)                       |  |  |

# Table 2. Genetic and related effects of isoprene

<sup>a</sup> +, positive;-, negative <sup>b</sup> LED, lowest effective dose; HID, highest ineffective dose; in-vitro tests, µg/mL; in-vivo tests, mg/kg bw /day; inh, inhalation; ip, intraperitoneal

gland adenomas in female mice. In one adequate study with rats, increased incidences were observed for benign neoplasms in the mammary gland in males and females and in the kidney and testis in males.

### 5.4 Other relevant data

Both rats and mice exhibited saturation kinetics when exposed to concentrations above 300 ppm [840 mg/m<sup>3</sup>]. The maximal rate of metabolism *in vivo*, which occurs via monoepoxides and diepoxide and subsequent epoxide hydration, is more than three times greater in mice than in rats. In-vitro studies and a physiological toxicokinetic model suggest that the rates of metabolism in humans is lower.

At high inhalation exposures, proliferative lesions in olfactory epithelium and lung were observed. Forestomach epithelial hyperplasia was detected at lower exposure levels in rats and mice. Adverse effects in reproductive organs of male and female mice were detected after high inhalation doses.

Isoprene did not induce mutations in bacteria or sister chromatid exchanges or chromosomal aberrations in animal cells *in vitro*. Isoprene induced sister chromatid exchanges and micronuclei in bone-marrow cells after inhalation exposure of mice.

Isoprene binds covalently to haemoglobin in vivo.

## 5.5 Evaluation

No epidemiological data relevant to the carcinogenicity of isoprene were available. There is *sufficient evidence* in experimental animals for the carcinogenicity of isoprene.

## **Overall evaluation**

Isoprene is *possibly carcinogenic to humans (Group 2B)*.

## 6. References

American Conference of Governmental Industrial Hygienists (1997) 1997 TLVs<sup>®</sup> and BEIs<sup>®</sup>, Cincinnati, OH

- Bogaards, J.J.P., Vanekamp, J.C. & van Bladeren, P.J. (1996) The biotransformation of isoprene and the two isoprene monoepoxides by human cytochrome P450 enzymes, compared to mouse and rat liver microsomes. *Chem-biol. Interact.*, **102**, 169–182
- Bond, J.A., Bechtold, W.E., Birnbaum, L.S., Dahl, A.R., Medinsky, M.A., Sun, J.D. & Henderson, R.F. (1991) Disposition of inhalated isoprene in B6C3F1 mice. *Toxicol. appl. Pharmacol.*, **107**, 494–503
- Budavari, S., ed. (1996) *The Merck Index*, 12th Ed., Whitehouse Station, NJ, Merck & Co., pp. 887–888
- Cox, L.A., Jr, Bird, M.G. & Griffis, L. (1996) Isoprene cancer risk and the time pattern of dose administration. *Toxicology*, **113**, 263–272

- Doerr, J.K., Hooser, S.B., Smith, B.J. & Sipes, I.G. (1995) Ovarian toxicity of 4-vinylcyclohexene and related olefins in B6C3F<sub>1</sub> mice: role of diepoxides. *Chem. Res. Toxicol.*, **8**, 963–969
- Filser, J.G., Csanády, G.A., Denk, B., Harmann, M., Kauffmann, A., Kessler, W., Kreuzer, P.E., Pütz, C., Shen, J.H. & Stei, P. (1996) Toxicokinetics of isoprene in rodents and humans. *Toxicology*, **113**, 278–287
- Gervasi, P.G., Citti, L., Del Monte, M., Longo, V. & Benetti, D. (1985) Mutagenicity and chemical reactivity of epoxidic intermediates of the isoprene metabolism and other structurally related compounds. *Mutat. Res.*, 156, 77–82
- IARC (1994) IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 60, Some Industrial Chemicals, Lyon, pp. 215–232
- International Labour Office (1991) Occupational Exposure Limits for Airborne Toxic Substances, 3rd. Ed. (Occupational Safety and Health Series No. 37), Geneva, pp. 234–235
- Lewis, R.J., Jr (1993) Hawley's Condensed Chemical Dictionary, 12th Ed., New York, Van Nostrand Reinhold Co., pp. 658–659
- Lide, D.R., ed. (1997) CRC Handbook of Chemistry and Physics, 78th Ed., Boca Raton, FL, CRC Press, p. 3-89
- Lybarger, H.M. (1995) Isoprene. In: Kroschwitz, J.I. & Howe-Grant, M., eds, *Kirk-Othmer Encyclopedia of Chemical Technology*, 4th Ed., Vol. 14, New York, John Wiley & Sons, pp. 934–952
- de Meester, C., Mercier, M. & Poncelet, F. (1981) Mutagenic activity of butadiene, hexachlorobutadiene and isoprene. In: Gut, I., Cikrt, M. & Plaa, G.L., eds, *Industrial and Environmental Xenobiotics*, Berlin, Springer, pp. 195–203
- Melnick, R.L., Roycroft, J.H., Chou, B.J., Ragan, H.A. & Miller, R.A. (1990) Inhalation toxicology of isoprene in F344 rats and B6C3F1 mice following two-week exposure. *Environ. Health Perspect.*, 86, 93–98
- Melnick, R.L., Sills, R.C., Roycroft, J.H., Chou, B.J., Ragan, H.A. & Miller, R.A. (1994) Isoprene, an endogenous hydrocarbon and industrial chemical, induces multiple organ neoplasia in rodents after 26 weeks of inhalation exposure. *Cancer Res.*, 54, 5333–5339
- Melnick, R.L., Sills, R.C., Roycroft, J.H., Chou, B.J., Ragan, H.A. & Miller, R.A. (1996) Inhalation toxicity and carcinogenicity of isoprene in rats and mice: comparisons with 1,3-butadiene. *Toxicology*, **113**, 247–252
- Mortelmans, K., Haworth, S., Lawlor, T., Speck, W., Tainer, B. & Zeiger, E. (1986) Salmonella mutagenicity tests: II. Results from the testing of 270 chemicals. *Environ. Mutag.*, 8 (Suppl. 7), 1–119
- NOES (1997) National Occupational Exposure Survey 1981-83, Unpublished data as of November 1997, Cincinnati, OH, United States Department of Health and Human Services, Public Health Service, Centers for Disease Control, National Institute for Occupational Safety and Health
- Placke, M.E., Griffis, L., Bird, M., Bus, J., Persing, R.L. & Cox, L.A., Jr (1996) Chronic inhalation oncogenicity study of isoprene in B6C3F<sub>1</sub> mice. *Toxicology*, **110**, 253–262
- Sun, J.D., Dahl, A.R., Bond, J.A., Birnbaum, L.S. & Henderson, R.F. (1989) Characterization of hemoglobin adduct formation in mice and rats after administration of [<sup>14</sup>C]butadiene or [<sup>14</sup>C]isoprene. *Toxicol. appl. Pharmacol.*, **100**, 86–95

- Tice, R.R., Boucher, R., Luke, C.A., Paquette, D.E., Melnick, R.L. & Shelby, M.D. (1988) Chloroprene and isoprene: cytogenetic studies in mice. *Mutagenesis*, **3**, 141–146
- United States National Toxicology Program (1995) *NTP Technical Report on Toxicity Studies of Isoprene (CAS No. 78-79-5) Administered by Inhalation to F344/N Rats and B6C3F1 Mice* (Toxicity Report Series No. 31), Research Triangle Park, NC, United States Department of Health and Human Services, Public Health Service, National Institutes of Health
- United States National Toxicology Program (1997) NTP Technical Report on the Toxicology and Carcinogenesis Studies of Isoprene (CAS No. 78-79-5) in F344/N Rats (Tech. Rep. Ser. No. 486; NIH Publication No. 97-3976), Research Triangle Park, NC, United States Department of Health and Human Services, Public Health Service, National Institutes of Health
- United States International Trade Commission (1994) Synthetic Organic Chemicals: US Production and Sales, 1993 (USITC Publ. 2810), Washington DC, United States Government Printing Office, p. 3-10
- United States National Library of Medicine (1997) *Hazardous Substances Data Bank (HSDB)*, Bethesda, MD [Record No. 620]
- Verschueren, K. (1996) Handbook of Environmental Data on Organic Chemicals, 3rd Ed., New York, Van Nostrand Reinhold, pp. 1162–1163
- Weitz, H.M. & Loser, E. (1989) Isoprene. In: Elvers, B., Hawkins, S., Ravenscroft, M. & Schulz, G., eds, Ullmann's Encyclopedia of Industrial Chemistry, 5th Ed., Vol. A14, New York, VCH Publishers, pp. 627–644
- WHO (1993) Guidelines for Drinking-Water Quality, 2nd Ed, Vol. 1, Recommendations, Geneva